Coya Therapeutics Q2 2025 net loss $6.1M; cash $29.8M; FDA decision on COYA 302 ALS IND by Aug 29

Coya Therapeutics, Inc.

2025-Q2 EPS reported -$0.80 vs consensus -$0.40 ▼ miss (-99.7%)

Net loss $6.1M vs $2.9M in Q2 2024; collaboration revenue fell to $0.2M from $3.4M.
Cash and equivalents $29.8M as of June 30, 2025.
R&D expenses $3.7M (down $0.9M YoY); G&A $2.9M (up $0.8M YoY).
FDA decision on IND for COYA 302 in ALS expected by August 29, 2025; upon acceptance, DRL milestone payment of $8.4M.
Additional catalysts: top-line data from FTD trial, IND for FTD by year-end.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.